Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.73 +9.3% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.73 +9.3% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
Earnings Routine +

PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results

PharmaCorp Rx Inc. Consolidates Eastern Canada Footprint as Q1 Revenue Surges 79%, Yet Margin Compression and Integration Pace Demand Caution

By The Northwire Desk — AI Analysis Jun 01, 2026 · 09:00 PCRX · 0.51 PharmaCorp Rx Inc.
Executive Summary
  • PharmaCorp Rx Inc. reported Q1 2026 financial results showing revenue of $7.2 million, a 79.4% year-over-year increase, driven by aggressive pharmacy acquisitions and organic same-store sales growth of 7.3%.
  • Adjusted EBITDA rose 30.1% to $0.9 million, while the company reported a net loss of $0.09 million, attributed to increased employee compensation and annual payment timing shifts rather than operational deterioration.
  • Cash on hand stands at $23.4 million as of March 31, 2026, down from $25.9 million at year-end 2025, reflecting the funding of multiple acquisitions.
  • The company confirmed the execution of its M&A pipeline, announcing definitive agreements to acquire 100% interest in eight pharmacies in Eastern Canada, one in Western Canada, and one in Ontario. Integration of three previously acquired pharmacies (October 2025) is proceeding as anticipated.
  • Historical progression shows a disciplined, step-by-step consolidation strategy: closing three pharmacies in October 2025 ($8.7M), filing a $100M shelf prospectus in October 2025, raising $23M via bought-deal in November 2025, and sequentially converting Letters of Intent (LOIs) into definitive agreements throughout Q1 2026.
Material Impact
  • The Q1 2026 results and M&A updates are in line with previous expectations set by the April and May 2026 announcements. The revenue and EBITDA growth directly correlate with the added store count and same-store sales momentum.
  • The net loss is a non-cash/timing artifact (compensation and payment shifts) and does not indicate a fundamental miss. Gross margin compression (38.8% vs 40.5% YoY) is noted but typical for rapid integration phases where fixed costs and onboarding expenses temporarily outpace revenue ramp-up.
  • The news confirms management's ability to convert LOIs into closed transactions while maintaining capital allocation discipline. It is a routine follow-up that validates the execution of the national consolidation thesis without introducing new, unexpected catalysts.
PCRX · Price
Company Overview
  • PharmaCorp Rx Inc. operates as a pharmacy consolidation platform in Canada, focusing on acquiring independent and PharmaChoice Canada bannered pharmacies.
  • Flagship Project: National expansion through a disciplined M&A strategy that preserves the legacy and community role of independent pharmacies while injecting operational, financial, and strategic expertise. The model relies on clustering locations in key urban markets and rural communities to maximize operational efficiency and patient continuity.
Read the original news release →

More from PharmaCorp Rx Inc.

Jun 29, 2026 · 07:16

PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy

M&A / Property May 25, 2026 · 09:27

PharmaCorp Rx Advances National Footprint with Definitive Acquisition, Pipeline Execution Validates Growth Strategy

M&A / Property May 01, 2026 · 17:00

PharmaCorp Rx Inc.

M&A / Property Apr 30, 2026 · 11:04

PharmaCorp Doubles Footprint, Cash Reserves Depleted by Aggressive Buyout

M&A / Property Apr 29, 2026 · 20:51

PharmaCorp Rx Confirms M&A Execution but Stock Stalls Near Dilutive Offering Price

Earnings Dec 11, 2025 · 19:04

Pharmacorp Rx enters deal to acquire pharmacy files

M&A / Property